Travere Therapeutics (TVTX) Earnings Dates, Call Summary & Reports

Q: When does Travere Therapeutics (TVTX) report earnings?

Travere Therapeutics (TVTX) is schdueled to report earning on Apr 30, 2026, After Close (Confirmed).

Q: What is Travere Therapeutics (TVTX) earnings time?

Travere Therapeutics (TVTX) earnings time is at Apr 30, 2026, After Close (Confirmed).

Q: Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

Q: What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

Q: What is TVTX EPS forecast?

TVTX EPS forecast for the fiscal quarter 2026 (Q1) is -0.23.

Compare

587 Followers

Earnings Data

Report Date

Apr 30, 2026

After Close (Confirmed)

Period Ending

2026 (Q1)

Consensus EPS Forecast

-0.23

Last Year’s EPS

-0.47

Same Quarter Last Year

Analyst Consensus

Strong Buy

Based on 14 Analysts Ratings

Earnings Call Summary

Q4 2025

Earnings Call Date:Feb 19, 2026|

% Change Since:

Earnings Call Sentiment|Positive

The call emphasized strong commercial momentum for FILSPARI with record demand, significant year-over-year revenue growth (FILSPARI +144% FY2025) and improved profitability/non-GAAP earnings, supported by a solid cash position and tangible pipeline progress (FSGS sNDA under review and pegtibatinase Phase III reactivation). Offsetting risks include an FDA information-request-driven delay to the FSGS PDUFA date, materially higher SG&A and rising gross-to-net discounts that will modestly compress near-term revenue and margins, and the emergence of new competitive entrants in IgAN. Overall, the positive operational and financial developments outweigh the challenges, but the regulatory timing and higher investment profile warrant continued monitoring.

Company Guidance

Management reiterated key near‑term milestones and financial expectations: the FILSPARI FSGS sNDA now has a PDUFA target action date of April 13, 2026; Q4 demand totaled 908 new patient start forms with FILSPARI U.S. net product sales of ~$103.3M in Q4 and ~$322M for FY2025 (144% YoY), contributing to company U.S. net product sales of $126.6M in Q4 and $410.5M for FY2025 (Thiola/Thiola EC $23.3M Q4 / $88.5M FY; license & collaboration revenue $3.1M Q4 / $80.3M FY); cash, cash equivalents and marketable securities were ~$322.8M at 12/31/25 (including a $40M CSL milestone and ~ $10M from Renalys), and net income for Q4 was $2.7M ($0.03/sh) with non‑GAAP net income $33.3M ($0.37/sh). For 2026 they expect FILSPARI gross‑to‑net to increase modestly to the mid‑20% range (up from ~20% in 2025) with the largest discount in Q1, moderate operating expense growth to fund the restarted Phase III HARMONY (pegtibatinase) trial and supply (HARMONY designed to enroll ~70 patients, 24‑week double‑blind primary endpoint measuring mean plasma total homocysteine change weeks 6–12), continued evidence generation and commercial investment (field force expanded from ~80 to >100), no near‑term need for additional capital, and they highlighted clinical metrics including PROTECT eGFR benefits (1.8 mL at 1 year and 3.7 mL at 2 years vs max‑dose irbesartan; total eGFR slope benefit 1.2 mL/min/yr), COMPOSE pegtibatinase tHcy reductions (~67% in Phase I/II), that ~2/3 of the addressable IgAN population have proteinuria <1.5 g/g, and that complete remission <0.3 g/day (80% on FILSPARI in a secondary analysis) was associated with an annual eGFR decline <1 mL/min/yr.

Record Demand and New Patient Starts

908 new patient start forms for FILSPARI in Q4 2025 (record quarter) with continued strong demand into Q1 2026; growth driven by both new prescribers and increased use among established prescribers, with broader community adoption.

Robust FILSPARI Revenue Growth

FILSPARI U.S. net product sales of approximately $103.3 million in Q4 2025 and $322 million for full year 2025, representing 144% year-over-year growth for the year.

Overall Company Revenue and Profitability Improvement

Company U.S. net product sales of $126.6 million in Q4 and total net product sales of $410.5 million for full year 2025; Q4 GAAP net income of $2.7 million ($0.03 per basic share) vs. net loss of $60.3 million in Q4 2024; non-GAAP net income of $33.3 million ($0.37) vs. non-GAAP loss prior year.

Pipeline Progress — FSGS Regulatory Milestone

sNDA for FILSPARI in FSGS under active FDA review with a new PDUFA target action date of April 13, 2026; company reports continued conviction in clinical profile and proteinuria as an approvable surrogate endpoint.

Pegtibatinase Advancement for Classical HCU

Resumed site activations for pivotal Phase III HARMONY and long-term extension ENSEMBLE after manufacturing process optimizations; Phase I/II COMPOSE showed ~67% reduction in total homocysteine in cohorts and durable effects out to one year for some patients.

Stronger Balance Sheet and One-Time Gains

Cash, cash equivalents and marketable securities of approximately $322.8 million as of December 31, 2025; Q4 benefitted from ~ $40 million CSL milestone, ~$10 million from Renalys transaction proceeds and a $25 million discontinued-operations milestone (Mirum), supporting liquidity.

Commercial Readiness and Field Expansion

Expanded commercial field team from ~80 to over 100 field-based personnel to support IgAN and potential FSGS launch; reported ~96% of patients have a pathway to reimbursement for FILSPARI.

Travere Therapeutics (TVTX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TVTX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Apr 30, 2026	2026 (Q1)	-0.23 / -	-0.47	―	―	―
Feb 19, 2026	2025 (Q4)	<0.01 / 0.03	-0.73	104.11% (+0.76)
Oct 30, 2025	2025 (Q3)	-0.30 / 0.28	-0.7	140.00% (+0.98)
Aug 06, 2025	2025 (Q2)	-0.31 / -0.14	-0.91	84.62% (+0.77)	―
May 01, 2025	2025 (Q1)	-0.57 / -0.47	-1.76	73.30% (+1.29)	―
Feb 20, 2025	2024 (Q4)	-0.56 / -0.73	-1.18	38.14% (+0.45)	―
Oct 31, 2024	2024 (Q3)	-0.67 / -0.70	1.97	-135.53% (-2.67)	―
Aug 01, 2024	2024 (Q2)	-0.79 / -0.91	-1.13	19.47% (+0.22)	―
May 06, 2024	2024 (Q1)	-0.96 / -1.76	-1.27	-38.58% (-0.49)	―
Feb 15, 2024	2023 (Q4)	-1.16 / -1.18	-1.03	-14.56% (-0.15)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TVTX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Feb 19, 2026	$29.30	$30.39	+3.72%
Oct 30, 2025	$29.65	$35.16	+18.58%
Aug 06, 2025	$17.24	$16.91	-1.91%
May 01, 2025	$20.76	$21.15	+1.88%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Travere Therapeutics (TVTX) report earnings?

Travere Therapeutics (TVTX) is schdueled to report earning on Apr 30, 2026, After Close (Confirmed).

What is Travere Therapeutics (TVTX) earnings time?

Travere Therapeutics (TVTX) earnings time is at Apr 30, 2026, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is TVTX EPS forecast?

TVTX EPS forecast for the fiscal quarter 2026 (Q1) is -0.23.